03.22.23 -- Delivering Genetic Editing Therapies To Market

Recent breakthroughs in gene editing are revolutionizing research and placing deliverable gene editing therapies within patients' grasps. Realizing this possibility, however, will rely on the effective development and manufacturing of new therapies at scale by partners with proven expertise in areas such as viral vector production and analytics.

Companies in the biopharmaceutical sector are striving for flexible and scalable cell culture platforms as they increase capacity and up-scale the production of viral vectors. Explore the benefits of using suspension cell lines in cell and gene therapy development and why adherent cell culture shouldn’t be left behind.

Gene therapy has revolutionized medicine since the early 1990s, and it continues to be one of the most promising fields in medicine. In the coming years, it will continue to become more relevant in the treatment and cure of some of the most severe diseases and disorders that affect humans.

The keys to success are establishing appropriate strategies and fundamental testing, expecting additional regulatory requests, being prepared for assay variability, recognizing the limits of current understanding, and ensuring that comparability studies will be possible by retaining material from preclinical batch runs and stability studies.